HC Wainwright Predicts Talphera FY2026 Earnings

Talphera, Inc. (NASDAQ:TLPH) – Equities researchers at HC Wainwright issued their FY2026 EPS estimates for Talphera in a research note issued to investors on Friday, June 5th. HC Wainwright analyst B. Folkes expects that the company will earn ($0.26) per share for the year. HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. HC Wainwright also issued estimates for Talphera’s FY2027 earnings at ($0.29) EPS, FY2028 earnings at ($0.18) EPS and FY2029 earnings at $0.13 EPS.

TLPH has been the topic of several other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Talphera in a report on Monday, April 20th. Westpark Capital assumed coverage on shares of Talphera in a research note on Thursday, April 30th. They set a “buy” rating and a $3.00 target price on the stock. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $3.00.

Talphera Stock Performance

NASDAQ:TLPH opened at $0.85 on Tuesday. Talphera has a one year low of $0.38 and a one year high of $1.57. The firm has a market cap of $43.95 million, a price-to-earnings ratio of -2.73 and a beta of 0.76. The firm’s fifty day moving average is $0.81 and its two-hundred day moving average is $0.94.

Talphera (NASDAQ:TLPH) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.03.

Institutional Investors Weigh In On Talphera

Several hedge funds have recently modified their holdings of TLPH. Group One Trading LLC boosted its stake in shares of Talphera by 3,224.0% during the 3rd quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock worth $27,000 after acquiring an additional 29,500 shares in the last quarter. Rosalind Advisors Inc. raised its position in shares of Talphera by 118.9% during the 3rd quarter. Rosalind Advisors Inc. now owns 4,385,757 shares of the company’s stock worth $3,917,000 after purchasing an additional 2,381,818 shares during the last quarter. Dauntless Investment Group LLC acquired a new position in shares of Talphera during the 3rd quarter worth about $89,000. Virtu Financial LLC acquired a new position in shares of Talphera during the 3rd quarter worth about $29,000. Finally, Nantahala Capital Management LLC raised its position in shares of Talphera by 75.3% during the 3rd quarter. Nantahala Capital Management LLC now owns 3,492,519 shares of the company’s stock worth $3,120,000 after purchasing an additional 1,500,000 shares during the last quarter. 37.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Vincent J. Angotti bought 213,310 shares of the stock in a transaction dated Friday, March 13th. The shares were acquired at an average cost of $0.59 per share, with a total value of $125,852.90. Following the purchase, the chief executive officer directly owned 800,705 shares in the company, valued at $472,415.95. The trade was a 36.31% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 3.50% of the stock is currently owned by insiders.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.